Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Free Report) Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $43.43, for a total transaction of $21,715.00. Following the transaction, the director now directly owns 79,333 shares of the company’s stock, valued at approximately $3,445,432.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Amphastar Pharmaceuticals Stock Down 0.9 %

AMPH opened at $41.94 on Thursday. The company has a fifty day moving average of $49.15 and a two-hundred day moving average of $51.60. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $35.62 and a fifty-two week high of $67.66. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 1.04 and a beta of 0.84. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.70 and a current ratio of 2.17.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Free Report) last announced its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.4 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective for the company.

Get Our Latest Report on Amphastar Pharmaceuticals

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently modified their holdings of AMPH. TD Asset Management Inc grew its position in shares of Amphastar Pharmaceuticals by 449.0% in the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock valued at $49,082,000 after purchasing an additional 649,001 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Amphastar Pharmaceuticals by 396.7% during the third quarter. Price T Rowe Associates Inc. MD now owns 808,731 shares of the company’s stock worth $22,727,000 after acquiring an additional 645,917 shares during the last quarter. Epoch Investment Partners Inc. boosted its position in Amphastar Pharmaceuticals by 348.7% during the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after acquiring an additional 460,473 shares during the last quarter. Boone Capital Management LLC acquired a new position in Amphastar Pharmaceuticals during the fourth quarter worth about $24,740,000. Finally, Bank of America Corp DE boosted its position in Amphastar Pharmaceuticals by 347.2% during the first quarter. Bank of America Corp DE now owns 290,737 shares of the company’s stock worth $10,903,000 after acquiring an additional 225,728 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Featured Articles

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.